Florida Opioid Prescribing Guidelines: Limits, Duties, and Penalties

Florida’s opioid prescribing guidelines cap most acute-pain opioid prescriptions at a three-day supply, require prescribers to consult the state’s prescription drug monitoring database before writing any controlled substance prescription, and impose detailed evaluation, documentation, and follow-up duties for anyone treating chronic pain with opioids. The rules sit primarily in Florida Statutes 456.44 and 893.055 and apply to every licensed prescriber in the state, from physicians and dentists to podiatrists and advanced practice providers.¹

The Three-Day Limit for Acute Pain

A prescriber may not write a Schedule II opioid prescription exceeding a three-day supply for acute pain. Acute pain is defined by statute as the normal, time-limited response to surgery, trauma, or acute illness. The three-day figure refers to the quantity of medication, not a three-day window after the prescription is written.²

A seven-day supply is permitted, but only when all three of the following are true:

The prescriber determines, in professional judgment, that more than three days of opioid therapy is medically necessary.
The prescription itself is marked “ACUTE PAIN EXCEPTION.”
The patient’s chart documents the acute condition and the lack of alternative treatment options that justify going past three days.

The “ACUTE PAIN EXCEPTION” notation is only needed when the prescription exceeds three days. A standard three-day acute-pain prescription requires no such label.²

Conditions Outside the Cap

The supply limits do not apply at all to pain arising from cancer, a terminal condition, palliative care, or traumatic injury with an Injury Severity Score of 9 or greater. A terminal condition means a progressive disease or surgical condition causing significant functional impairment that will result in death within one year if it runs its normal course. These carve-outs sit inside the statute’s definition of “acute pain,” so prescriptions for these situations are outside the supply caps entirely.¹ Chronic nonmalignant pain is governed by its own separate rules, covered further below.²

Checking E-FORCSE Before You Prescribe

Before prescribing or dispensing any controlled substance to a patient aged 16 or older, the prescriber or a designee must consult E-FORCSE, Florida’s Prescription Drug Monitoring Program. E-FORCSE tracks dispensing data for Schedules II through V.³ The check is required every time, not just at the start of treatment.

Consultation is not required if:

The system is nonoperational or inaccessible due to a temporary technological or electrical failure.
The patient is under 16.
The prescription is for a nonopioid controlled substance listed in Schedule V.
The patient has been admitted to hospice.

A common misread: the Schedule V exception is limited to nonopioid Schedule V drugs. Schedule V opioids still trigger the database check.²

Evaluation and Documentation Before Starting Opioids

Florida requires a full workup before opioid therapy begins. The prescriber must complete and record a medical history covering prior pain treatments, current medications, and relevant family history, together with a physical examination that addresses the nature and intensity of the pain, any underlying conditions, and how the pain affects daily function.¹

A written, individualized treatment plan is also required. It has to include a formal assessment of the patient’s risk for substance abuse. Before treatment starts, the prescriber must discuss the risks and benefits of opioid therapy, including the risks of addiction and physical dependence, and document informed consent.

Rules for Chronic Nonmalignant Pain

Chronic nonmalignant pain is defined as pain unrelated to cancer that persists beyond the usual course of the disease or injury causing it, or more than 90 days after surgery. Once a patient crosses into that category, further obligations kick in.

Written Controlled Substance Agreement

Before chronic opioid therapy begins, prescriber and patient must sign a written controlled substance agreement covering:

The number and frequency of prescriptions and refills the patient can expect.
The conditions under which therapy may be discontinued, such as violating the agreement.
A requirement that controlled substances for chronic nonmalignant pain come from a single treating prescriber unless another arrangement is authorized and documented.

The single-prescriber clause is where many chronic pain patients stumble. Filling a controlled substance prescription from another provider without the treating prescriber’s documented authorization can end the agreement.¹

Reassessment Every Three Months

Chronic opioid patients must be seen at intervals no longer than three months. At each visit, the prescriber evaluates whether treatment is working, whether opioid therapy remains appropriate, the patient’s progress toward goals, and any adverse effects. The prescriber must also maintain a written plan for detecting aberrant drug-related behavior, which can include random drug screening, pill counts, and review of E-FORCSE data. If noncompliance surfaces, the prescriber is expected to modify or discontinue therapy and, when appropriate, refer the patient to an addiction medicine specialist.

Electronic Prescribing

Prescribers who maintain electronic health records must transmit prescriptions electronically, including controlled substances in Schedules II through V. The mandate applied at license renewal or by July 1, 2021, whichever came first.⁴

Statutory exceptions include:

The prescriber and dispenser are the same entity.
The prescription cannot be transmitted under the current NCPDP SCRIPT Standard.
The practitioner holds a department hardship waiver (up to one year) for economic hardship, technology limitations outside the prescriber’s control, or another exceptional circumstance.
Electronic prescribing would delay care in a way that could adversely affect the patient’s medical condition.
The drug is prescribed under a research protocol.
The prescription requires FDA-mandated elements that cannot appear in electronic format.
The patient is a nursing home resident or is receiving hospice care.
The prescriber or patient decides it is in the patient’s best interest to compare drug prices among pharmacies, and the prescriber documents that decision.

Using one of these exceptions does not excuse the E-FORCSE check. The e-prescribing rule and the database consultation rule are separate obligations.⁵

Pain Management Clinic Registration

Clinics that focus on pain treatment generally must register with the Florida Department of Health. A pain-management clinic is any facility that either advertises pain-management services or has a majority of its patients in a given month receiving prescriptions for opioids, benzodiazepines, barbiturates, or carisoprodol for chronic nonmalignant pain. Each location registers separately, even under a shared business name.⁶

Every registered clinic must name a designated physician responsible for compliance. If that physician leaves, the clinic has 10 days to name a replacement. Certain clinics are exempt, including those wholly owned and operated by board-eligible or board-certified anesthesiologists, physiatrists, rheumatologists, or neurologists, and multispecialty practices where qualified pain specialists perform interventional procedures routinely billed with surgical codes. Designated physicians must file quarterly reports to the Board of Medicine or Board of Osteopathic Medicine covering new and repeat controlled-substance patients, patients discharged for drug abuse or diversion, and out-of-state patients treated at the clinic.⁷

Naloxone

Florida does not require co-prescribing naloxone with opioids, but access is broad. Under Section 381.887, any authorized prescriber may prescribe and dispense an emergency opioid antagonist to a patient at risk of overdose or to someone in a position to help, such as a family member. A 2022 statewide standing order from the State Surgeon General authorizes pharmacists to dispense naloxone to emergency responders without a patient-specific prescription. The CDC recommends offering naloxone to all opioid patients, with particular attention to those on 50 MME per day or more, those with a history of overdose, those also taking benzodiazepines, and patients with a history of substance use disorder.⁸

What Happens if You Break These Rules

Violating Florida’s opioid prescribing rules exposes a prescriber to discipline from their licensing board. The Board of Medicine, Board of Osteopathic Medicine, Board of Dentistry, and Board of Pharmacy each have authority to investigate and sanction licensees. Outcomes range from fines and mandatory continuing education to probation, license suspension, and revocation, with steeper penalties for repeat offenses.

Failing to check E-FORCSE before prescribing a controlled substance is independently actionable. Pharmacist penalty guidelines, the only published board schedule available, start at $1,000 for a first offense and climb to $10,000 with suspension for repeat violations. Physician penalties escalate on a similar curve through Board of Medicine disciplinary proceedings.

Prescribers who move from negligent prescribing into deliberate overprescribing face criminal exposure. Federal law provides up to 20 years in prison per count for a practitioner convicted of distributing a Schedule II controlled substance outside the bounds of legitimate medical practice, and mandatory minimums of 20 years apply when distribution results in death. Florida prosecutors can also charge under the state’s drug abuse prevention laws in Chapter 893.

The everyday risk is more mundane. Nearly every rule above creates a documentation duty: the missing three-month follow-up note, the absent risk assessment, the seven-day prescription without the “ACUTE PAIN EXCEPTION” label. Those gaps are what open board investigations, and the chart is what closes them.

1
The Florida Legislature. Florida Statutes 456.44 – Controlled Substance Prescribing
2
Florida Department of Health. Frequently Asked Questions
3
The Florida Legislature. Florida Statutes 893.055 – Prescription Drug Monitoring Program
4
Florida Senate. Florida Statutes 456.42 – Written Prescriptions for Medicinal Drugs
5
Florida Board of Osteopathic Medicine. Electronic Prescribing Requirements
6
The Florida Legislature. Florida Statutes 458.3265 – Pain-Management Clinics
7
Florida Department of Health. Pain Management Clinic Inspection Authority
8
Centers for Disease Control and Prevention. When to Offer Naloxone to Patients